Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada

Background Islet transplantation offers an effective treatment for selected people with type 1 diabetes and intractable hypoglycaemia. Long-term experience, however, remains limited. We report outcomes from a single-centre cohort up to 20 years after islet transplantation. Methods This cohort study included patients older than 18 years with type 1 diabetes undergoing allogeneic islet transplantation between March 11, 1999, and Oct 1, 2019, at the University of Alberta Hospital (Edmonton, AB, Canada). Patients who underwent islet-after-kidney transplantation and islet transplantation alone or islet transplantation before whole-pancreas transplantation ( follow-up was censored at the time of whole-pancreas transplantation) were included. Patient survival, graft survival ( fasting plasma C-peptide >0.1 nmol/L), insulin independence, glycaemic control, and adverse events are reported. To identify factors associated with prolonged graft survival, recipients with sustained graft survival (>= 90% of patient follow-up duration) were compared with those who had non-sustained graft survival (<90% of follow-up duration). Multivariate binary logistic regression analyses were done to determine predictors of sustained graft survival. Findings Between March 11, 1999, and Oct 1, 2019, 255 patients underwent islet transplantation and were included in the analyses (149 [58%] were female and 218 [85%] were White). Over a median follow-up of 7.4 years (IQR 4.4-12.2), 230 (90%) patients survived. Median graft survival was 5.9 years (IQR 3.0-9.5), and graft failure occurred in 91 (36%) patients. 178 (70%) recipients had sustained graft survival, and 77 (30%) had non-sustained graft survival. At baseline, compared with patients with non-sustained graft survival, those with sustained graft survival had longer median type 1 diabetes duration (33.5 years [IQR 24.3-41.7] vs 26.2 years [17.0-35.5]; p=0.0003), median older age (49.4 years [43.5-56.1] vs 44.2 years [35.4-54.2]; p=0.0011), and lower median insulin requirements (0.53 units/kg per day [0.45-0.67] vs 0.59 units/kg per day [0.48-0.70]; p=0.032), but median HbA(1c) concentrations were similar (8.2% [7.5-9.0] vs 8.5% [7.8-9.2]; p=0.23). 201 (79%) recipients had insulin independence, with a Kaplan-Meier estimate of 61% (95% CI 54-67) at 1 year, 32% (25-39) at 5 years, 20% (14-27) at 10 years, 11% (6-18) at 15 years, and 8% (2-17) at 20 years. Patients with sustained graft survival had significantly higher rates of insulin independence (160 [90%] of 178 vs 41 [53%] of 77; p<0.0001) and sustained improvements in glycaemic control mixed-main-effects model group effect, p<0.0001) compared with those with non-sustained graft survival. Multivariate analyses identified the combined use of anakinra plus etanercept (adjusted odds ratio 7.5 [95% CI 2.7-21.0], p<0.0001) and the BETA-2 score of 15 or higher (4.1 [1.5-11.4], p=0.0066) as factors associated with sustained graft survival. In recipients with sustained graft survival, the incidence of procedural complications was lower (23 [5%] of 443 infusions vs 17 [10%] of 167 infusions; p=0.027), whereas the incidence of cancer was higher (29 of [16%] of 178 vs four [5%] of 77; p=0.015) than in those with non-sustained graft survival; most were skin cancers (22 [67%] of 33). End-stage renal disease and severe infections were similar between groups. Interpretation We present the largest single-centre cohort study of long-term outcomes following islet transplantation. Although some limitations with our study remain, such as the retrospective component, a relatively small sample size, and the absence of non-transplant controls, we found that the combined use of anakinra plus etanercept and the BETA-2 score were associated with improved outcomes, and therefore these factors could inform clinical practice. Copyright (C) 2022 Elsevier Ltd. All rights reserved.

Automated summary

This study reports the long-term outcomes of islet transplantation in a single-center cohort, including patient survival, graft survival, insulin independence, glycemic control, and adverse events. The study found that the combined use of anakinra plus etanercept and the BETA-2 score were associated with improved outcomes.